Kirsten Merx

Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Tanja Lahaye, Birte Riehm, Ute Berger et al. · Cancer · 2005 · 226 citations

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

Kirsten Merx, M. C. Muller, Sebastian Kreil et al. · Leukemia · 2002 · 171 citations

Hematological Malignancy, Chromatin Structure, Epigenetic Regulation +11

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

Martin C. Müller, Norbert Gattermann, Tanja Lahaye et al. · Leukemia · 2003 · 125 citations

Hematological Malignancy, First-line Therapy, Medicine +9

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Ralf‐Dieter Hofheinz, S. Hegewisch-Becker, Volker Kunzmann et al. · International Journal of Cancer · 2021 · 95 citations · Full text

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Peter Paschka, Martin C. Müller, Kirsten Merx et al. · Leukemia · 2003 · 92 citations

Hematological Malignancy, Residual Disease, Molecular Monitoring +10